Factibilidad de análisis biomolecular en base a la metilación del promotor de O6-metilguanina-ADN metiltransferasa mediante técnica de PCR anidado en glioblastoma multiforme en el Hospital Carlos Van Buren, Chile

Abstract

Glioblastoma multiforme is the most frequent subtype of gliomas in adults, with a poor survival rate after diagnosis. Without treatment, the mean survival time doesn’t exceed 3 months after diagnosis, increasing up to 12 to 15 months if the optimal treatment is given, including surgical resection, radiotherapy and chemotherapy using temozolomide. The main objective of this study is to evaluate the feasibility to do a biomolecular analysis of histological samples at Carlos Van Buren Hospital using nested PCR technique to determine methylation of MGMT promoter between 2010 and 2014. As an dditional objective, we pretended to evaluate the correlation between mean survival time and MGMT promoter methylation status. The MGMT methylation status was studied in twelve samples, achieving a 57,1% amplification success. An 83,3% was found in a non-methyl ated status, with 9.2 months of mean survival time, in contrast to 21 months in the methylated group (p = 0.15). We concluded that nested PCR technique is feasible to do in our center, requiring prospective studies to evaluate a predictive value, although an increased mean survival time after diagnosis and methylated status was related.